GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Cyclically Adjusted PS Ratio

ProPhase Labs (ProPhase Labs) Cyclically Adjusted PS Ratio : 2.14 (As of Apr. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Cyclically Adjusted PS Ratio?

As of today (2024-04-27), ProPhase Labs's current share price is $4.71. ProPhase Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $2.20. ProPhase Labs's Cyclically Adjusted PS Ratio for today is 2.14.

The historical rank and industry rank for ProPhase Labs's Cyclically Adjusted PS Ratio or its related term are showing as below:

PRPH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.57   Med: 1.85   Max: 14.95
Current: 2.25

During the past years, ProPhase Labs's highest Cyclically Adjusted PS Ratio was 14.95. The lowest was 0.57. And the median was 1.85.

PRPH's Cyclically Adjusted PS Ratio is ranked worse than
51.11% of 135 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.21 vs PRPH: 2.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ProPhase Labs's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.194. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.20 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProPhase Labs Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ProPhase Labs's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Cyclically Adjusted PS Ratio Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.87 8.57 4.76 4.64 2.05

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 3.53 3.24 1.93 2.05

Competitive Comparison of ProPhase Labs's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, ProPhase Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Cyclically Adjusted PS Ratio falls into.



ProPhase Labs Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ProPhase Labs's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.71/2.2
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ProPhase Labs's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.194/129.4194*129.4194
=0.194

Current CPI (Dec. 2023) = 129.4194.

ProPhase Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.375 99.695 0.487
201406 0.106 100.560 0.136
201409 0.282 100.428 0.363
201412 0.581 99.070 0.759
201503 0.369 99.621 0.479
201506 0.137 100.684 0.176
201509 0.259 100.392 0.334
201512 -0.581 99.792 -0.753
201603 0.059 100.470 0.076
201606 0.060 101.688 0.076
201609 0.080 101.861 0.102
201612 0.045 101.863 0.057
201703 0.043 102.862 0.054
201706 0.112 103.349 0.140
201709 0.190 104.136 0.236
201712 0.338 104.011 0.421
201803 0.299 105.290 0.368
201806 0.281 106.317 0.342
201809 0.211 106.507 0.256
201812 0.354 105.998 0.432
201903 0.201 107.251 0.243
201906 0.143 108.070 0.171
201909 0.239 108.329 0.286
201912 0.271 108.420 0.323
202003 0.163 108.902 0.194
202006 0.312 108.767 0.371
202009 0.331 109.815 0.390
202012 0.445 109.897 0.524
202103 0.839 111.754 0.972
202106 0.603 114.631 0.681
202109 0.614 115.734 0.687
202112 2.909 117.630 3.201
202203 2.536 121.301 2.706
202206 1.510 125.017 1.563
202209 1.195 125.227 1.235
202212 1.343 125.222 1.388
202303 1.069 127.348 1.086
202306 0.785 128.729 0.789
202309 0.487 129.860 0.485
202312 0.194 129.419 0.194

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProPhase Labs  (NAS:PRPH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ProPhase Labs Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus

ProPhase Labs Announces Launch of Redesigned Corporate Website

By sperokesalga sperokesalga 04-25-2023